Is there any Western research on this?

Very little, and none that reproduces the central claims. The body of work is almost entirely from one Russian institute, and it has stood unreplicated elsewhere for decades.

Can Pancragen replace diabetes medication?

No, and this is the one place in this family where getting it wrong has a fast and measurable cost. There is no trial evidence that Pancragen affects glucose control in humans. Stopping or reducing a prescribed diabetes treatment in favour of it means giving up a known effect for an unevidenced one, with damage that accumulates quietly.

Does the oral form work?

Both oral and injected forms are sold with the same claims. For most peptides the route changes everything, because digestion destroys them. That the same effect is claimed either way is a reason for scepticism rather than reassurance.

Anti-aging & longevity

Pancragen

Lys-Glu-Asp-Trp · KEDW peptide · Pancragen bioregulator

PreclinicalReviewed 18 Aug 2026

Pancragen is one of the short peptide bioregulators developed at the St Petersburg Institute of Bioregulation and Gerontology, each of which is assigned to a specific tissue. It is assigned to pancreatic tissue and marketed at people with disordered glucose control. That audience is the reason this page is more cautious than the rest of the family: the condition it is sold into has effective treatments and a measurable cost to leaving them.

It is sold to people with prediabetes and type 2 diabetes, sometimes in bundles beside GLP-1 compounds that do have trial evidence. The pairing lends borrowed credibility in one direction only.

Everything else about Pancragen is inherited. It rests on one institute's work, spanning decades and never replicated by anyone outside it, and on a proposed mechanism no other compound on this site shares: a peptide two to four amino acids long, said to reach the nucleus and switch on the genes of one tissue. Glucose is one of the few things this family's buyers actually measure, which cuts both ways: a real effect would be visible, and so is the harm from substituting this for a treatment that works. That argument and the structural objection to it are set out under Khavinson bioregulator in the glossary, once, because they apply identically to all of them.

How it works

Pancragen is proposed to enter the cell nucleus and bind DNA directly, promoting expression of genes associated with the pancreas. The claim is expression of genes involved in insulin production and pancreatic cell renewal, described in the originating literature as restoring function in ageing pancreatic tissue.

No independent group has demonstrated any of that. Because the mechanism is described as genomic rather than receptor-mediated, none of the pharmacokinetic reasoning used elsewhere on this site applies: there is no receptor occupancy to model, and no dose-response curve established outside the originating work.

Vocabulary on this page

Batch number: An identifier for one production run. It is what makes a certificate of analysis mean anything about the vial in your hand.
Khavinson bioregulator: A family of very short peptides from one St Petersburg institute, each assigned to a different organ, on the claim that they act directly on DNA rather than through a receptor.
Injection site: Where on the body an injection is given. Rotating between sites is standard practice for anything given repeatedly.
Peptide: A short chain of amino acids: the same building blocks as a protein, in a chain short enough to behave differently.
Protocol: One compound, with a dose, a frequency and a length: the plan, as opposed to what was actually taken.

The whole glossary →

Quick reference

Commonly described dose: 1 mg–2 mg
How often: Daily for a 10-day course, repeated a few times a year
Route: Subcutaneous or Oral
Where: Abdomen, Thigh
Timing: No timing effect established.
Storage once mixed: Refrigerated, 21 days
Cycle: 10 days on, Months between courses off

These describe what sources report, not what you should do. Full detail and provenance in the dosing section below.

Price index

$2.75 – $4.75per mg

Across 5 vendors, normalised per milligram and confirmed by a person.

Confirmed listings for this compound, cheapest per milligram first.
Vendor	Size	Price	Per mg
Liberty Peptides	20 mg	$55.00	$2.75
Swiss Chems	20 mg	$59.95	$3.00
Core Peptides	20 mg	$63.00	$3.15
Umbrella Labs	10 mg	$35.00	$3.50
BioLongevity Labs	20 mg	$94.97	$4.75

Is this price moving? →Every compound we price →

Email me when Pancragen gets cheaper

Ranked on price alone. We sell nothing, take no payment for placement, and use no affiliate links — listing a price is not a recommendation to buy. Prices are what the vendor listed when we last looked, not a live quote.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

Support for the pancreas

Published review

The claim Pancragen is sold on, and the only one the originating literature makes for it.

EvidenceReported in Russian clinical and animal work from a single institute. Not registered — not blinded to contemporary standards — and never independently replicated.

Regulatory status — United States

Not approved for human use in the United States, the European Union or the United Kingdom. Some peptides in this family are registered in Russia as supplements or medicines. Pancragen is sold elsewhere as a research chemical.

Last reviewed 18 Aug 2026. Regulatory positions in this category change frequently; we date this line so you can see how current it is.

Identity and clearance

Molecule

Class: Short synthetic peptide bioregulator
Length: 4 amino acids

Sequence

Lys-Glu-Asp-Trp

Most of this family shares a glutamic acid and aspartic acid core, differing only in one or two flanking residues.

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Dose protocols reported in sources, with the source of each.
Goal	Dose	Frequency	Route	Units, 10 mg vial	Source	Start this protocol
Course described in community sources	1 mg – 2 mg	Daily for a 10-day course, repeated a few times a year	SubcutaneousThe 10-day course is the pattern described across this whole family. It is convention, not a finding. No dose-ranging study establishes it, and the same figures appear for peptides assigned to entirely different organs.	10–20 u	Community practice	Start this

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.

Cycling

Community practice

10 days on, Months between courses off.

Described consistently across the family, and consistently without a study behind it.

Work out what to draw

Pre-filled with a 20 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.

Draw to 20 units on a 1 mL U-100 syringe. That is 0.2 mL, containing 2 mg of Pancragen.

Concentration10mg / mL

Volume drawn0.2mL

Doses per vial10doses

Per unit100mcg / unit

20 units sits exactly on a printed line.

Get a shareable image Read the profile

Bioalmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.

Open this calculation in the full calculator

Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.

Safety

Reported effects

Generally described as well toleratedPublished review
Reported in the Russian literature
That literature is not designed to detect adverse events reliably, so an absence of reports is weak evidence of safety rather than good evidence of it.
Injection site irritationCommunity practice
Occasionally reported
Everything elseCommunity practice
Unknown
No adverse event has been systematically recorded outside the originating programme.

When to stop

Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
An injection site that becomes hot, spreading or produces pus.
Any new or unexplained symptom you would ordinarily see a doctor about.

Interactions and situations that need care

Active or previous cancerAvoid
The proposed mechanism is switching on gene expression in a target tissue. Whatever one makes of that claim, deliberately pursuing it in someone with malignancy has no supporting evidence and an obvious direction of concern.
Pregnancy and breastfeedingAvoid
No reproductive or developmental safety data, for a compound whose claimed mechanism is gene expression.
Diabetes of any type, prediabetes, or any prescribed glucose-lowering treatmentUse caution
This is sold directly into a condition with effective treatments and consequences for leaving it untreated. A compound with no human evidence has no place substituting for one, and the risk here is not a side effect — it is the treatment that gets displaced.
Expecting the Russian literature to mean what a trial meansUse caution
It is real research, produced over decades, and it is not evaluable the way a registered randomised trial is. Four decades without independent replication is information in its own right, and it points one way.

What to expect

HonestlyThere is no human efficacy data for this compound, so there is no evidence-based timeline to give. Any site publishing a week-by-week schedule of expected effects has invented it.

No independent group has replicated the central findings of this family in forty years.
The proposed mechanism, short peptides acting directly on chromatin, is not how anything else on this site is understood to work.
Peptides in this family differing by one amino acid are assigned to different organs. If that seems like a lot of specificity for one residue, that is the right reaction.
The 10-day course pattern is identical across compounds assigned to entirely different tissues, which is a convention, not a dosing finding.
Nothing here establishes an effect in people, and the absence of reported harm is not the same as evidence of safety.

Storage and handling

Freeze-dried powder: Refrigerated at 2–8 °C, protected from light.
After mixing: Refrigerated at 2–8 °C. Do not freeze once mixed.
Long-term, frozen: Unopened powder is stable at −20 °C or colder.

Printable one-pager How to reconstitute a vial, step by step

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it. More on assessing quality and COAs.

White cake, clear solution
Standard for a very short peptide.
Collapsed cake or cloudy solution
Heat damage or degradation. Do not use it.

Questions

Is there any Western research on this?: Very little, and none that reproduces the central claims. The body of work is almost entirely from one Russian institute, and it has stood unreplicated elsewhere for decades.
Can Pancragen replace diabetes medication?: No, and this is the one place in this family where getting it wrong has a fast and measurable cost. There is no trial evidence that Pancragen affects glucose control in humans. Stopping or reducing a prescribed diabetes treatment in favour of it means giving up a known effect for an unevidenced one, with damage that accumulates quietly.
Does the oral form work?: Both oral and injected forms are sold with the same claims. For most peptides the route changes everything, because digestion destroys them. That the same effect is claimed either way is a reason for scepticism rather than reassurance.

References

Short peptide bioregulators: the Khavinson programme and its evidential limits
Russian gerontology and bioregulation literature, 2014 · Body of largely unregistered clinical and animal work from a single institute
Humans and animals
Reports tissue-specific effects across a family of di-, tri- and tetrapeptides, attributed to direct interaction with chromatin. Trial registration, pre-specified protocols, blinding to contemporary standards and independent replication are largely absent, and no group outside the originating institute has reproduced the central findings.
Commonly reported community protocols
Bioalmanac editorial summary of public community sources, 2026 · Not a study
Records the 10-day course pattern described across this family in public discussion. Carries no evidential weight about safety or effect.

Related compounds

GHK-Cu

A naturally occurring copper-binding tripeptide with a long history in topical skincare research. Injected use is not what the research studied.

Ipamorelin

A selective growth hormone secretagogue that prompts a short pulse of GH release. Widely used, and supported almost entirely by early pharmacology rather than outcome trials.

CJC-1295

A GHRH analogue that raises growth hormone by amplifying the body's own release signal. Sold in two forms whose durations differ by two orders of magnitude.

Tesamorelin

A GHRH analogue approved by the FDA for reducing excess visceral fat in HIV-associated lipodystrophy. The only compound in this category with completed phase 3 trials.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice. No clinician reviews these pages.

Page last updated 18 Aug 2026